Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Other solid neoplasm 1

Conditions

Melanoma 105Carcinoma, Renal Cell 38Leukemia, Myeloid, Acute 36Neoplasm Metastasis 31Neoplasms 22Breast Neoplasms 22Lymphoma, Non-Hodgkin 21Kidney Neoplasms 20Leukemia 18Carcinoma, Non-Small-Cell Lung 18Skin Neoplasms 17Neuroblastoma 17Ovarian Neoplasms 16Colorectal Neoplasms 16Recurrence 14Leukemia, Lymphocytic, Chronic, B-Cell 14Lymphoma 13Myelodysplastic Syndromes 10Uveal Melanoma 9Precursor Cell Lymphoblastic Leukemia-Lymphoma 9Lymphoma, Follicular 9Head and Neck Neoplasms 9Uterine Cervical Neoplasms 8Multiple Myeloma 8Congenital Abnormalities 8Triple Negative Breast Neoplasms 7Stomach Neoplasms 7Lung Neoplasms 7Hodgkin Disease 7Squamous Cell Carcinoma of Head and Neck 6

Interventions

Lenalidomide 4Gemcitabine 4Dexamethasone 4Cyclophosphamide 4Bortezomib 4Nivolumab 3Cisplatin 3Carboplatin 3vandetanib 2tumor necrosis factor-alpha, CNGRC fusion protein, human 2pomalidomide 2pembrolizumab 2liposomal doxorubicin 2fludarabine 2durvalumab 2capivasertib 2Radiosurgery 2Paclitaxel 2Doxorubicin 2Bevacizumab 2Anthropogenic Effects 2venetoclax 1umbralisib 1ublituximab 1tremelimumab 1tivozanib 1ricolinostat 1regorafenib 1pazopanib 1niraparib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Disease Progression × Interleukin-2 × Clear all
NCT03546426 2024-10-01

MESOVAX

Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS

Phase 1 Active not recruiting
18 enrolled
Other solid neoplasmThoracic

Mesothelioma, Malignant, Disease Progression

Data powered by HemOnc (CC BY 4.0) Colophon âš¡